Neurogene (NGNE) Return on Capital Employed (2014 - 2026)

Neurogene has reported Return on Capital Employed for 13 years, with the latest figure at 43.1% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1428.0% year-over-year to 43.1%; the trailing twelve-month figure through Mar 2026 stood at 43.1% (down 1428.0% YoY), and the FY2025 full-year result was 34.94%, down 365.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 43.1%, down from 38.01% in the prior quarter.
• The five-year high for Return on Capital Employed was 28.82% in Q1 2025, with the low at 60.66% in Q3 2023.
• Historically, Return on Capital Employed has averaged 43.17% across 5 years, with a median of 41.76% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2206 bps — and 2024, when it soared 2492 bps.
• Neurogene's Return on Capital Employed stood at 50.79% in 2022, then rose by 18 bps to 41.76% in 2023, then advanced by 16 bps to 35.19% in 2024, then retreated by 8 bps to 38.01% in 2025, then fell by 13 bps to 43.1% in 2026.
• The last three Return on Capital Employed figures came in at 43.1% (Q1 2026), 38.01% (Q4 2025), and 35.02% (Q3 2025), per Business Quant data.